|
1.
|
|
11 p, 726.2 KB |
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
/
Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Amonkar, Mayur (Merck & Co., Inc.. Center for Observational and Real World Evidence) ;
Fuchs, Charles S. (Yale School of Medicine. Yale Cancer Center) ;
Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ;
Özgüroğlu, Mustafa (Istanbul University-Cerrahpaşa. Department of Internal Medicine, Medical Oncology, and Clinical Trial Unit) ;
Bang, Yung-Jue (Seoul National University College of Medicine. Department of Internal Medicine) ;
Chung, Hyun Cheol (Yonsei University College of Medicine. Department of Medical Oncology) ;
Muro, Kei (Aichi Cancer Center Hospital) ;
Goekkurt, Eray (University Cancer Center Hamburg. North-German Trial Center for Innovative Oncology) ;
Benson, Al B. (Northwestern University. Robert H. Lurie Comprehensive Cancer Center) ;
Sun, Weijing (University of Kansas. Department of Internal Medicine and Medical Oncology) ;
Wainberg, Zev A. (David Geffen School of Medicine at UCLA. Department of Medicine and Hematology and Oncology) ;
Norquist, Josephine M. (Merck & Co., Inc.. Center for Observational and Real World Evidence) ;
Chen, Xinqun (Merck & Co., Inc.. Department of Medical Oncology) ;
Shih, Chie-Schin (Merck & Co., Inc.. Department of Medical Oncology) ;
Shitara, Kohei (National Cancer Center Hospital. Department of Gastrointestinal Oncology) ;
Universitat Autònoma de Barcelona
In the primary analysis population (i. e. , PD-L1 combined positive score [CPS] ≥ 1) of the phase 3 KEYNOTE-061 study (NCT02370498), pembrolizumab did not significantly prolong overall survival or progression-free survival. [...]
2021 -  10.1007/s10120-021-01200-w
Gastric Cancer, Vol. 24 (august 2021) , p. 1330-1340
|
|
|
2.
|
|
11 p, 588.4 KB |
Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma : results from the randomised phase III KEYNOTE-062 study
/
Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Valderrama, A. (Center for Observational and Real-World Evidence, Merck) ;
Bang, Yung-Jue (Seoul National University College of Medicine) ;
Fuchs, C. S. (Yale University Cancer Center) ;
Shitara, Kohei (National Cancer Center Hospital East, Kashiwa, Japan) ;
Janjigian, Y. Y. (Memorial Sloan Kettering Cancer Center) ;
Qin, S. (PLA Cancer Centre of Nanjing Bayi Hospital) ;
Larson, T. G. (Minnesota Oncology Hematology) ;
Shankaran, V. (Seattle Cancer Care Alliance) ;
Stein, S. (Yale University Cancer Center) ;
Norquist, J. M. (Center for Observational and Real-World Evidence, Merck) ;
Kher, U. (Department of Medical Oncology, Merck) ;
Shah, S. (Department of Medical Oncology, Merck) ;
Alsina, Maria (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
In the randomised phase III KEYNOTE-062 study, pembrolizumab was non-inferior to chemotherapy for overall survival in patients with programmed death-ligand 1 (PD-L1)-positive [combined positive score (CPS) ≥1] advanced gastric/gastroesophageal junction (GEJ) cancer. [...]
2021 - 10.1016/j.esmoop.2021.100189
ESMO open, Vol. 6 (august 2021)
|
|
|
3.
|
|
11 p, 388.8 KB |
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
/
Arnold, D. (Instituto CUF de Oncologia (I.C.O.), Lisboa) ;
Fuchs, C. S. (Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA) ;
Tabernero, Josep (Universitat Autònoma de Barcelona) ;
Ohtsu, A. (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ;
Zhu, A. X (Massachusetts General Hospital (Boston)) ;
Garon, E. B. (Hematology Oncology, David Geffen School of Medicine at UCLA Translational Research in Oncology-US Network, Santa Monica, USA) ;
Mackey, J. R. (Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada) ;
Paz Ares, L. (Hospital Universitario 12 de Octubre (Madrid)) ;
Baron, A. D. (Division of Hematology Oncology, California Pacific Medical Center, San Francisco, USA) ;
Okusaka, T. (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan) ;
Yoshino, Takayuki (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ;
Yoon, H. H. (Division of Medical Oncology, Mayo Clinic, Rochester, USA) ;
Das, M. (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Ferry, David (Oncology, Eli Lilly and Company, Bridgewater, USA) ;
Zhang, Y (Oncology, Eli Lilly and Company, Bridgewater, USA) ;
Lin, Y (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Binder, P. (Oncology, Eli Lilly and Company, Bridgewater, USA) ;
Sashegyi, A.. (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Chau, Ian (Department of Medicine, Royal Marsden Hospital, Sutton, UK)
Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of vascular endothelial growth factor receptor 2, has been approved for treating gastric/gastroesophageal junction, non-small-cell lung, and metastatic colorectal cancers. [...]
2017 - 10.1093/annonc/mdx514
Annals of oncology, Vol. 28 (september 2017) , p. 2932-2942
|
|
|
4.
|
|
9 p, 1.1 MB |
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab
/
Fuchs, Charles S. (Harvard Medical School) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Tomášek, Jiří (Masaryk University (Czech Republic)) ;
Chau, Ian (Royal Marsden Hospital (Regne Unit)) ;
Melichar, Bohuslav (Univerzity Palackeho a Fakultni nemocnice (Czech Republic)) ;
Safran, Howard (Brown University Oncology Research Group (USA)) ;
Tehfe, Mustapha A. (Centre Hospitalier de Montréal (Canada)) ;
Filip, Dumitru (Spitalul Judetean de Urgenta (Romania)) ;
Topuzov, Eldar (Northwest State Medical University na II Mechnikov) ;
Schlittler, Luis (Hospital da Cida de Passo Fundo (Brasil)) ;
Udrea, Anghel Adrian (Medisprof SRL (Romania)) ;
Campbell, William (Hospital Herrera Llerandi (Guatemala)) ;
Brincat, Stephen (Sir Anthony Mamo Oncology Centre (Malta)) ;
Emig, Michael (Lilly Deutschland GmbH (Germany)) ;
Melemed, Symantha A. (Lilly Corporate Center (USA)) ;
Hozak, Rebecca R. (Lilly Corporate Center (USA)) ;
Ferry, David (Lilly Corporate Center (USA)) ;
Caldwell, C. William (Lilly Corporate Center (USA)) ;
Ajani, Jaffer A. (The University of Texas MD Anderson Cancer Center (USA)) ;
Universitat Autònoma de Barcelona
Angiogenesis inhibition is an important strategy for cancer treatment. Ramucirumab, a human IgG1 monoclonal antibody that targets VEGF receptor 2 (VEGFR2), inhibits VEGF-A, -C, -D binding and endothelial cell proliferation. [...]
2016 - 10.1038/bjc.2016.293
British Journal of Cancer, Vol. 115, Issue 8 (October 2016) , p. 974-982
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
